real-time news and commentary for investors
Monday, Jun 24
The negative commentary isn't letting up for Allergan (AGN -9.2%) as the shares are under...
The negative commentary isn't letting up for Allergan (AGN -9.2%) as the shares are under significant pressure following Friday's FDA letter on a non-clinical approval pathway for generic Restasis and subsequent chatter out of analysts at Deutsche and Leerink. Piper's David Amsellem joins the fray saying that while proving bioequivalence "will not necessarily be simple … there are a number of generic companies with the sophistication to at least pursue the product, and certainly a path forward without clinical trials makes the opportunity that more attractive." Price target lowered to $79 from $90.